Diabetes & Metabolic
Immunology & Other
A global biopharmaceutical company transforming access to healthcare through affordable innovation — reaching patients everywhere with lifesaving therapies.
WHO WE ARE
We are a global biopharmaceutical company with the belief that everyone, everywhere deserves access to affordable quality medicines. From biosimilars that democratize biologic therapy to novel biologics addressing unmet needs, Biocon is transforming lives at scale — guided by innovation, scientific rigor, and a steadfast commitment to patients.
Expanding access to life-saving biologic medicines globally
Affordable generic formulations and complex APIs
Addressing unmet medical needs with breakthrough science
Accelerating drug innovation and development worldwide
Trusted therapies across key therapeutic areas
Building the next generation of biopharma talent
Key Milestones
View Full Legacy →Founded
Started in a garage in Bengaluru with a vision to make biopharmaceuticals affordable and accessible worldwide.
Biosimilars
Biocon became the first Indian company to receive USFDA approval for a Lovastatin — a breakthrough in global compliance.
Markets
Biocon went public with India's largest biotech IPO at the time, listing on both the Bombay and National Stock Exchanges.
Oncology
Launched India's first indigenously developed monoclonal antibody for head and neck cancer.
FDA Approval
Biocon Biologics received landmark U.S. FDA approval, making cancer treatment more affordable globally.
World First
Semglee (Insulin Glargine) received historic U.S. FDA approval as the world's first-ever interchangeable biosimilar.
Acquisition
A transformative acquisition expanding Biocon Biologics into 120+ countries — one of the world's top five biosimilar companies.
Integration
Successfully integrated across 120 countries including North America, Europe, Japan, Australia and Emerging Markets.
Revenue
Biocon Biologics surpassed the USD 1 billion revenue milestone driven by robust growth across global markets.
Unified Enterprise
13% YoY revenue growth and 200bps EBITDA expansion delivering on the promise of integration.
Founded
Started in a garage in Bengaluru with a vision to make biopharmaceuticals affordable and accessible worldwide.
Biosimilars
Biocon became the first Indian company to receive USFDA approval for a Lovastatin — a breakthrough in global compliance.
Markets
Biocon went public with India's largest biotech IPO at the time, listing on both the Bombay and National Stock Exchanges.
Oncology
Launched India's first indigenously developed monoclonal antibody for head and neck cancer.
FDA Approval
Biocon Biologics received landmark U.S. FDA approval, making cancer treatment more affordable globally.
World First
Semglee (Insulin Glargine) received historic U.S. FDA approval as the world's first-ever interchangeable biosimilar.
Acquisition
A transformative acquisition expanding Biocon Biologics into 120+ countries — one of the world's top five biosimilar companies.
Integration
Successfully integrated across 120 countries including North America, Europe, Japan, Australia and Emerging Markets.
Revenue
Biocon Biologics surpassed the USD 1 billion revenue milestone driven by robust growth across global markets.
Unified Enterprise
13% YoY revenue growth and 200bps EBITDA expansion delivering on the promise of integration.
Global markets reached with affordable biosimilars
Professionals across the Biocon Group worldwide
In our pipeline across oncology, diabetes & immunology
Benefit from our biosimilars, generics and APIs each year
Our Commitment
At Biocon, sustainability is integral to our business purpose. We execute a progressive ESG strategy aligned with stakeholder expectations — advancing the health of patients, people, and the planet to achieve key UN Sustainable Development Goals. In 2024, Biocon achieved an S&P Global ESG Score of 69, placing us in the 98th percentile among global biotechnology peers.
Learn more about our ESG journey
Despite a complex geopolitical environment, Biocon delivered margin expansion and disciplined execution through a pivotal year of integration, creating a unified biopharma entity with stronger global reach.
Read MorePress Release
News
Biosimilars
At Biocon, Diversity, Equity, and Inclusion is not a programme — it is the foundation of how we build teams, pursue science, and create impact. We believe that diverse perspectives lead to better innovation, stronger decisions, and more relevant outcomes for the patients we serve. We foster a collaborative environment where curiosity is rewarded, ownership is expected, and every team member is empowered to make a real difference in global healthcare.
Tell us what you need — whether you are a patient, partner, investor, or talent. We will connect you to the right team at Biocon.